Abstract
The updated 2016 World Health Organization (WHO) Classification of Tumours of the Central Nervous System (CNS) has incorporated molecular parameters into pathological diagnosis, for the first time in the molecular era. While it has led to the more precise diagnoses of well-understood entities and the better comprehension of less-understood entities, its practical application has also created some concerns whether or not genotypes predominate over phenotypes in tumor diagnostics. In response to these concerns, the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy–Not Official WHO (cIMAPCT-NOW) was established under the sponsorship of the International Society of Neuropathology to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications. cIMPACT has thus far published five updates on the proposal and clarification of existing and new terms and entities. Also, recent studies have shown that WHO grading based on histology has lost its prognostic relevance, which necessitates novel, improved grading criteria. We herein highlight the current status of clinical application of WHO 2016 classification and cIMPACT proposals, and the future endeavor to incorporate DNA methylation profiling of the CNS tumors for better clinical decision-making to achieve a goal of precision medicine for each patient with brain tumors.
Similar content being viewed by others
References
Louis DN, Ohgaki H, Wiestler OD et al (2016) WHO classification of tumours of the central nervous system revise, 4th edn. IARC, Lyon
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1
Louis DN, Aldape K, Brat DJ et al (2017) Announcing cIMPACT-NOW: the consortium to inform molecular and practical approaches to CNS tumor taxonomy. Acta Neuropathol 133(1):1–3. https://doi.org/10.1007/s00401-016-1646-x
Perry A (2016) WHO’s arrived in 2016! An updated weather forecast for integrated brain tumor diagnosis. Brain Tumor Pathol 33:157–160. https://doi.org/10.1007/s10014-016-0266-4
Louis DN, Perry A, Burger P et al (2014) International society of neuropathology-haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24(5):429–435. https://doi.org/10.1111/bpa.12171
Sonoda Y, Yokoo H, Tanaka S et al (2019) Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors. Brain Tumor Pathol 36:56–62. https://doi.org/10.1007/s10014-019-00337-y
Arita H, Narita Y, Yoshida A et al (2015) IDH1/2 mutation detection in gliomas. Brain Tumor Pathol 32:79–89. https://doi.org/10.1007/s10014-014-0197-x
Masui K, Harachi M, Cavanee W et al (2020) Codependency of metabolism and epigenetics drives cancer progression: a review. Acta Histochem Cytochem 53:1–10. https://doi.org/10.1267/ahc.20002
Toru K (2017) Molecular mechanism involved in gliomagenesis. Brain Tumor Pathol 34:1–7. https://doi.org/10.1007/s10014-017-0278-8
Louis DN, Wesseling P, Paulus W et al (2018) cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol 135(3):481–484. https://doi.org/10.1007/s00401-018-1808-0
Louis DN, Giannini C, Capper D et al (2018) cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma. IDH-mutant Acta Neuropathol 135(4):639–642. https://doi.org/10.1007/s00401-018-1826-y
Brat DJ, Aldape K, Colman H et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136(5):805–810. https://doi.org/10.1007/s00401-018-1913-0
Louis DN, Ellison DW, Brat DJ, Aldape K, Capper D, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, von Deimling A, Wesseling P (2019) cIMPACT-NOW: a practical summary of diagnostic points from round 1 updates. Brain Pathol 29(4):469–472. https://doi.org/10.1111/bpa.12732
Ellison DW, Hawkins C, Jones DTW et al (2019) cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol 137(4):683–687. https://doi.org/10.1007/s00401-019-01987-0
Shirahata M, Ono T, Stichel D et al (2018) Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136(1):153–166. https://doi.org/10.1007/s00401-018-1849-4
Yoda R, Marxen T, Longo L et al (2019) Mitotic index thresholds do not predict clinical outcome for IDH-mutant astrocytoma. J Neuropathol Exp Neurol 78:1002–1010. https://doi.org/10.1093/jnen/nlz082
Brat D, Aldape K, Colman H et al (2020) cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139:603–608. https://doi.org/10.1007/s00401-020-02127-9
Komori T (2019) The anticipated revision of the grading citeria for adult isocitrate dehydrogenase-mutant diffuse glioma within the neuro-oncology community. Neuro-Oncology 21(12):1485–1486
Capper D, Jones D, Sill M et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555(7697):469–474. https://doi.org/10.1038/nature26000
Aoki K, Natsume A (2019) Overview of DNA methylation in adult diffuse gliomas. Brain Tumor Pathol 36:84–91. https://doi.org/10.1007/s10014-019-0339-w
Jaunmuktane Z, Capper D, Jones D et al (2019) Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. Acta Neuropathol 7:24. https://doi.org/10.1186/s40478-019-0668-8
Ceccarelli M, Barthel F, Malta T et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563. https://doi.org/10.1016/j.cell.2015.12.028
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare no potential conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Onizuka, H., Masui, K. & Komori, T. Diffuse gliomas to date and beyond 2016 WHO Classification of Tumours of the Central Nervous System. Int J Clin Oncol 25, 997–1003 (2020). https://doi.org/10.1007/s10147-020-01695-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-020-01695-w